FDA approves new nonhormonal medication for menopause hot flashes
May 15, 2023Medical Communications FDA, HRT, Veozah, hot flashes, menopause
The US Food and Drug Administration (FDA) has announced its approval of Veozah (fezolinetant), an oral medication to treat moderate …
FDA relaxes blood donation regulations for MSM
May 12, 2023Medical Communications FDA, HIV, HIV/AIDS, blood donation
The US Food and Drug Administration (FDA) has released updated guidance for blood donation which relaxes the rules for donations …
Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies
May 12, 2023Sales and Marketing Angelini Pharma, JCR Pharmaceuticals, Neurology, epilepsy
Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global development and commercialisation agreement for …
Bellerophon Therapeutics completes phase 3 study for fibrotic interstitial lung disease drug
May 12, 2023Medical Communications Bellerophon Therapeutics, Cardiology, clinical trial, lung disease
US clinical stage biotherapeutics company Bellerophon Therapeutics has announced that the last patient has completed its phase 3 REBUILD study, …
FDA advisory committee votes in support of favourable benefit-risk profile for ARS Pharmaceuticals’ allergic reaction treatment
May 12, 2023Research and Development ARS Pharmaceuticals, Allergic Disorders, FDA, allergy
US-based biopharmaceutical company ARS Pharmaceuticals has announced that the US Food and Drug Administration (FDA)’s Pulmonary-Allergy Drug Advisory Committee (PADAC) …
FDA advisory committee votes in favour of OTC contraceptive pill
May 11, 2023Medical Communications Contraception, FDA, OTC, Perrigo, contraception
Perrigo Company has announced that the US Food and Drug Administration’s (FDA) Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, …
Otsuka and Lundbeck gain FDA approval for supplemental New Drug Application for dementia drug
May 11, 2023Medical Communications FDA, Lundbeck, Neurology, Otsuka Pharmaceuticals, alzheimer's disease, dementia
Japan-based healthcare company Otsuka Pharmaceutical and Danish pharma company Lundbeck have announced that the US Food and Drug Administration (FDA) …
AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD
May 11, 2023Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology
AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …
FDA pre-meeting report raises concerns over Sarepta’s gene therapy for Duchenne muscular dystrophy
May 11, 2023Medical Communications Duchenne Muscular Dystrophy, FDA, Musculo-skeletal disorder, Sarepta Therapeutics, gene therapy
The US Food and Drug Administration (FDA) has released a report in preparation for its 12 May decision on Sarepta …
Gilead acquires XinThera to strengthen pipeline in oncology and inflammation
May 10, 2023Sales and Marketing Gilead, Oncology, XinThera, inflammation, oncology
Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, …
Eyenovia announces FDA approval of first ophthalmic spray for mydriasis
May 10, 2023Research and Development Eyenovia, FDA, Opthalmology, mydriasis, ophthalmology
Ophthalmic technology company Eyenovia has announced that the US Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine …
Sobi acquires CTI BioPharma Corporation for $1.7bn
May 10, 2023Medical Communications CTI, acquisition, sobi
Swedish Orphan Biovitrum, aka Sobi, has announced that it had entered into a ‘plan of merger’ with CTI BioPharma Corp …
Thermo Fisher and Pfizer collaborate on NGS-based cancer tests
May 10, 2023Medical Communications Cancer, NGS, Oncology, Pfizer, Thermo Fisher Scientifitic, oncology
Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to advance next-generation sequencing (NGS)-based cancer …
FlyPharma Europe, Vienna: the early bird deal for FlyPharma Vienna closes on 24 May
May 9, 2023Business Services, Conferences Conference, flypharma
Act now! The early bird deal for FlyPharma Vienna closes on 24 May. Contact Angela Heath, conference director, email angela@samedanltd.com for …
Pharmacists in England given wider prescribing powers to relieve GP pressure
May 9, 2023Medical Communications GP, NHS England, pharmacists
NHS England had announced that pharmacists in England will be given wider prescribing powers to relieve pressure put on GPs. …
AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death
May 9, 2023Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …
CureVac and GSK begin phase 1 trial for mRNA flu vaccine candidates
May 9, 2023Medical Communications CureVac, GSK, Virology, clinical trial, mrna, vaccines
CureVac and GSK have announced that the first patient in the phase 1 section of their combined phase 1/2 trial …
Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal
May 9, 2023Research and Development Boehringer Ingelheim, Rare Diseases, cell programming, ginkgo bioworks, undruggable targets
German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks have announced a partnership to …
Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease
May 5, 2023Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug
Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …
FDA accepts sNDA for Optinose’s XHANCE
May 5, 2023Medical Communications Ear Nose & throat, FDA, Nasal Spray, optinose, sNDA
Optinose has announced that the US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
